Abstract
Malaria is a major health and economic threat to about 40% of the worlds population. The absence of effective vaccines and widespread resistance to many of the current antimalarials make this disease an urgent target for the scientific community. As a developing world disease, most of the efforts towards new drugs have been from academic and government supported projects. This has recently changed with the emergence of new funding mechanisms and public-private partnerships (PPP). The purpose of this review is to highlight the different approaches used to discover new antimalarial agents, including target-based approaches, derivatization of known antimalarial pharmacophores, drug repositioning from non-malaria indication and cell-based screening. Specific examples are provided to illustrate the pros and cons in the context of how to best address the ever-increasing drug resistance and how to cost-effectively identify new antimalarials. More attention is given to relatively mature programs that have gone through extensive SAR study, pharmacology and/or toxicity studies in the last ten years.
Keywords: Malaria, drug resistance, artemisinin, plasmodium, DHODH, aminoquinoline, Farnesyl transferase, hybrid compounds, antimalarials, antimalarial pharmacophores, cell-based screening
Current Medicinal Chemistry
Title: Road Towards New Antimalarials – Overview of the Strategies and their Chemical Progress
Volume: 18 Issue: 6
Author(s): Tao Wu, Advait S. Nagle and Arnab K. Chatterjee
Affiliation:
Keywords: Malaria, drug resistance, artemisinin, plasmodium, DHODH, aminoquinoline, Farnesyl transferase, hybrid compounds, antimalarials, antimalarial pharmacophores, cell-based screening
Abstract: Malaria is a major health and economic threat to about 40% of the worlds population. The absence of effective vaccines and widespread resistance to many of the current antimalarials make this disease an urgent target for the scientific community. As a developing world disease, most of the efforts towards new drugs have been from academic and government supported projects. This has recently changed with the emergence of new funding mechanisms and public-private partnerships (PPP). The purpose of this review is to highlight the different approaches used to discover new antimalarial agents, including target-based approaches, derivatization of known antimalarial pharmacophores, drug repositioning from non-malaria indication and cell-based screening. Specific examples are provided to illustrate the pros and cons in the context of how to best address the ever-increasing drug resistance and how to cost-effectively identify new antimalarials. More attention is given to relatively mature programs that have gone through extensive SAR study, pharmacology and/or toxicity studies in the last ten years.
Export Options
About this article
Cite this article as:
Wu Tao, S. Nagle Advait and K. Chatterjee Arnab, Road Towards New Antimalarials – Overview of the Strategies and their Chemical Progress, Current Medicinal Chemistry 2011; 18 (6) . https://dx.doi.org/10.2174/092986711794927748
DOI https://dx.doi.org/10.2174/092986711794927748 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia
Current Diabetes Reviews Gene Therapy to Improve Pancreatic Islet Transplantation for Type 1 Diabetes Mellitus
Current Diabetes Reviews p75NTR as a Therapeutic Target for Neuropsychiatric Diseases
Current Molecular Pharmacology Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets Nucleic Acid-Based Therapeutics for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets Developing Effective Therapy for Duchenne Muscular Dystrophy (DMD): Challenges and Promises
Current Chemical Biology Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Editorial
Current Drug Therapy Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Synthetic and Biological Aspects of Thiadiazoles and their Condensed Derivatives: An Overview
Current Topics in Medicinal Chemistry Tetrahydrobiopterin Pathway may Provide Novel Molecular Targets for Acute and Long Term Efficacy of Mood-Regulating Drugs
Current Pharmacogenomics and Personalized Medicine Resveratrol and Ischemic Preconditioning in the Brain
Current Medicinal Chemistry Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
Current Pharmaceutical Biotechnology Delivery Systems for Biopharmaceuticals. Part I: Nanoparticles and Microparticles
Current Pharmaceutical Biotechnology